| Blog | AI's Red Carpet Year | Discovery, AI |
| Blog | Toxys ReproTracker | Safety Assessment, DART, 3Rs |
| Blog | The Mouse and the Machine | RMS, Refinement, Animal Welfare |
| Blog | AI Eyes Preclinical Oncology Imaging | Discovery, AI |
| Media Coverage | Regulation and drug policy: Industry predictions for 2025 | Discovery, AI,3Rs |
| Media Coverage | The Evolution of Eco-Conscious Endotoxin Testing | Microbial, Trillium, 3Rs, Alternatives |
| Blog | The Next Generation of Drug Development | AI, Toxicology, AMAP |
| Blog | PDX Tumor Organoids: A New Tool in the Drug Testing Realm | Discovery, In Vitro Technologies, 3Rs |
| Blog | GEN News: 2025 Trends: Organoids | AMAP, Discovery |
| Blog | GEN News: 2025 Trends: Organoids | AMAP, Discovery |
| Featured News | CNS Drug Discovery and Design Made Smarter | AI, AMAP |
| Blog | FAQs About Recombinant Testing Validation | 3Rs, Microbial |
| Press Release | Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions | Safety Assessment, AI, Toxicology |
| Featured News | Shifting Technology Platforms | AMAP |
| Blog | Paving the Way for Virtual Control Groups | AMAP, Safety Assessment, 3Rs |
| Video | Organoids: Some Assembly Required | AMAP, Discovery, 3D models |
| Media Coverage | Is AI truly transforming drug development, or are we still navigating through the hype? | AI, Alternatives, Discovery |
| Media Coverage | Tracing the regulatory evolution of recombinant testing and future compendial recognition | Microbial, Trillium, Alternatives |
| Media Coverage | Tracing the regulatory evolution of recombinant testing and future compendial recognition | Microbial, Trillium, Alternatives |
| Blog | A Status Report on Cell-Based Protein Arrays | Alternatives, 3Rs, Discovery |
| Podcast | Rethinking Toxicology: The Future of NAMs in Agrochemicals | AMAP, 3Rs |
| Podcast | All About Spheroids | AMAP, 3Rs |
| Blog | Will Non-Animal Approaches Replace Some or All of Animal Testing? | AMAP, 3Rs |
| Press Release | Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform | Discovery, AI |
| Blog | A Promising Advance in AI-Enabled Drug Discovery | Discovery, AMAP, AI |
| Video | iPSCs: Cellular Shape Shifters | CDMO, Alternatives, stem cells |
| Publication | Opportunities and Insights from Pharmaceutical Companies on the Current use of New Approach Methodologies in Nonclinical Safety Assessment | AMAP, NAMs |
| Slide Deck | Prediction of Respiratory Toxicity Using Human and Rat 3D Airway Models | AMAP, NAMs |
| Webinar | NAMs-based Prediction of Respiratory Toxicity Using Human and Rat Airway Models | NAMs |
| Blog | Traditional or Alternative: That is the New Question | AMAP, 3Rs, Alternatives |
| Press Release | Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development | Oncology, AMAP, 3Rs, organoids, AI |
| Blog | Virtual Controls in PDX Tumor Studies | Discovery, AMAP, 3Rs |
| Featured News | Fast-Tracking Drug Development with AI-driven Pathology | AMAP, Digital Pathology, 3Rs |
| Scientific Poster | Influence of Culture Conditions and Donor Material on Phenotypic Features of PDX-Derived Breast Cancer Tumoroid Lines | AMAP, PDX models |
| Scientific Poster | Safety Profile Assessment for IND-Enabling Studies: Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) | AMAP, PDX models |
| Blog | Can New Approach Methodologies De-Risk Drug Development? | Alternative Platforms, AMAP |
| Slide Deck | NAM-based Prediction of Point of Contact Respiratory Toxicity Using Human and Rat Airway Models | AMAP, 3Rs, Alternatives |
| Featured News | Bring Safer, Smarter Therapies to Patients Faster | Alternatives, AMAP |
| Media Coverage | Mini organs offer alternative method for predicting drug safety and efficacy | NAMs, AMAP, 3D models, Organoids |
| Featured News | Paving the Way for Enhanced Drug Development | Alternate Platforms, AMAP |
| Blog | Customized 3Rs Solutions for GEMS Colonies | 3Rs, Animal Welfare |
| Podcast | Behind the Breakthroughs: Rethinking Animal Research with the 3Rs | AMAP,3Rs, Alternatives |
| Podcast | Is animal testing even needed anymore? | Alternatives, NAMs |
| Slide Deck | NAM-Based Prediction of Respiratory Toxicity Using Human and Rat Airway Models | AMAP, NAMs, Alternatives |
| Blog | Flow Cytometry: A Tool for New Approach Methodologies | AMAP,3Rs, Alternatives |
| Slide Deck | Towards Regulatory Acceptance of In Vitro Models for Inhaled Chemical Hazard Assessment | AMAP,3Rs, Alternatives |
| Scientific Poster | Modelling Complex Immune Processes Using Tonsil Organoids to Aid Drug Discovery | AMAP,3Rs, Alternatives |
| Scientific Poster | Incorporating Complex In Vitro Models into Drug Discovery and Development Pipelines | AMAP,3Rs, Alternatives |
| Scientific Poster | A Plug-and-play μFluidic Adaptor: Transforming Standard Well Plates into Dynamic Microphysiological Systems | AMAP,3Rs, Alternatives |
| Media Coverage | The Shift From LAL To Recombinant: What Your Lab Should Expect | AMAP,3Rs, Alternatives |
| Slide Deck | Prioritizing Complex in vitro Models for the Scaled and Routine Adoption of NAMs | AMAP,3Rs, Alternatives |
| Blog | Monoclonal Antibodies: Animal Testing vs. Alternatives | AMAP, 3Rs, Monoclonal Antibodies |
| Blog | Researching Crimes of Opportunity | 3Rs, RMS, PathogenBinder |
| Webinar | Secure Regulatory Approval of Complex Lung Models Through Collective Momentum | AMAP, Inhalation Tox, Organoids |
| Blog | Rapid Quarantine of Mouse Models | 3Rs, RMS |
| Podcast | From Tumor to Treatment: How PDX Models are Powering Cancer Breakthroughs | AMAP, PDX models |
| Media Coverage | Planning for a Dual-Method Future | NAMs, Alternatives, Microbial |
| Blog | Rapid Quarantine of Mouse Models | 3Rs, RMS |
| Slide Deck | Our Next Gen Preclinical Journey: Embracing NAMs | 3Rs, Alternatives |
| Webinar | Maximize Safer, Targeted Biologic Development with Smarter NAMs-Based Off-Target Screening | AMAP, 3Rs, Retrogenix |
| Featured News | New Approach Methodologies for Drug Discovery and Development | NAMs, AMAP |
| Media Coverage | How AI And Mini-Organs Could Replace Testing Drugs On Animals | NAMs, Alternatives |
| Media Coverage | Backed by Big Pharma, NIH foundation launches program to push animal testing alternatives across regulatory finish line | NAMs, Alternatives |
| Blog | How Merging NAMs and Traditional Models Look in Discovery | NAMs, Automation, Discovery |
| Media Coverage | Future-Proofing with AI in Mind: Q&A with Laura Lotfi | NAMs, 3Rs, AI, Safety Assessment |
| Media Coverage | Drug developers rethink submission strategies amidst FDA’s new AI tool | NAMs, 3Rs, AI, Safety Assessment |
| Media Coverage | Animal testing alternatives to dominate, but not overnight | NAMs, 3Rs, AI, Safety Assessment |
| Press Release | Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing | 3Rs, Alternatives, Discovery |
| Scientific Poster | Implementing low-stress handling across a global organization: Big improvements in animal welfare through small changes in human behavior | 3Rs, Animal Welfare |
| Scientific Poster | Welfare recommendations for harmonized care of laboratory rabbits (Oryctolagus cuniculus) across a global organization | 3Rs, Animal Welfare |
| Slide Deck | Integrating All 3Rs Using a Scientifically-Supported Theory of Behavior Change | 3Rs, Alternatives |
| Scientific Poster | New Alternative Method (NAM) for Predictive Genotoxicity using MicroPhysiological System (MPS) | NAMs |
| Slide Deck | Evolving Endocrine Disruption Strategies | AMAP, NAMs, Alternatives |
| Podcast | Regulations and Realities in Lab Animal Use | NAMs, 3Rs, animal testing |
| Featured News | AI Uncovers New Treatment Opportunities | NAMs, Alternatives |
| Podcast | Off-Target, On-Point: How Retrogenix® Reduces Risk and Animal Use | NAMs, Alternatives, 3Rs |
| Blog | The End of Rabbit Pyrogen Testing in the EU | NAMs, Alternatives, 3Rs |
| Blog | A Consortium Aims to Make CAR-T's Faster and More Affordable | Alternatives, in vitro assays |
| Blog | New Immunoassay Tools: From Samples to Results Faster | NAMs, Immunoassays |
| Blog | Reimagining Oncology Preclinical Science | NAMs |
| Blog | New Approach Methodologies: A New Terrain for Antibody Testing | NAMs, Alternatives, antibodies |
| Webinar | Antibody Discovery Meets NAMs: Pathways to Faster, Safer Biologics | NAMs, Alternatives, 3Rs |
| Scientific Poster | Assessing cardiac liability of compounds using new approach methodologies (NAMs) | NAMs |
| Blog | An Alternative to the Animal-Based DART Screens | NAMs, Alternatives, 3Rs, DART |
| Featured News | NAMs in Predictive Safety: From Genotoxicity to Endocrine Disruption | NAMs |
| Featured News | Next-Generation Sequencing: New Hope for Cancer Patients | NAMs |
| Blog | PCR-based screening: A Solid 3Rs Choice During Quarantine | 3Rs, RMS |
| Blog | PCR-based screening: A Solid 3Rs Choice During Quarantine | 3Rs, RMS |
| Webinar Series | Advance Your DART Programs with New Approach Methodologies (NAMs) | NAMs |
| Media Coverage | The Newest New Approach Methodologies | NAMs, AI |
| Video | Research Animals: Handle With Care | 3Rs, animal refinement |
| Presentation | Rethinking Antibody Development to IND: Early Risk Mitigation, Target Specificity, & mRNA-LNP Delivery Strategies | AI, Machine Learning |
| Podcast | Choosing Wisely: The Ethics, Science, and Emotion Behind Species Selection | Alternatives, 3Rs |
| Blog | The Quantum Advantage | AI, CADD |
| Featured News | Industry Leaders Signal a Turning Point in Drug Development | NAMs |
| Featured News | Industry Leaders Signal a Turning Point in Drug Development | NAMs |
| Podcast | Charles River CSO Calls For Collaboration On Non-Animal Models | NAMs |
| Blog | How Global Trends Help or Hamper Pharma Business | NAMS, Alternatives |
| Podcast | Catalyst Conversations Podcast: Driving Drug Discovery and Development Forward | NAMS, AI |
| Blog | What’s Hot in 2026: Agentic Laboratory Technology | Automation, NAMs |
| Blog | What’s Hot in 2026: Organoids Unbound | NAMS, Discovery |
| Blog | What’s Hot in 2026: New Approach Methodologies | NAMS |
| Featured News | Monoclonal Antibodies: Science in Motion | NAMS |
| Featured News | Advance Drug Development with AI-Powered New Approach Methodologies | NAMS, AI |
| Podcast | Breathing New Life into Toxicology: Human-Relevant Models in Action | NAMS |
| Featured News | Rethinking Developmental Toxicity Testing with New Approach Methodologies | NAMS |
| Featured News | Advancing Animal Welfare and Transparency with USARO Agreement | NAMs, Animal welfare |
| Media Coverage | The rise of new approach methodologies in drug and chemical safety | NAMs |
| Media Coverage | Pre-clinical trial giant eyes organ-on-a-chip companies after activist investor pressure | NAMs |
